Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Other neoplasm 1

Conditions

Precancerous Conditions 12Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 3Esophageal Neoplasms 2Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Tongue Neoplasms 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Myelodysplastic Syndromes 1Mouth Neoplasms 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Leukoplakia, Oral 1Laryngeal Neoplasms 1Keratosis, Actinic 1

Interventions

Endoscopy 2High-Throughput Screening Assays 1Genetic Linkage 1Esomeprazole 1Erlotinib Hydrochloride 1Endoscopy, Digestive System 1Endoscopic Mucosal Resection 1Comparative Genomic Hybridization 1Biopsy 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Barrett Esophagus × Biopsy × Other neoplasm × Clear all
NCT00566800 2013-09-17

Erlotinib in Treating Patients With Barrett Esophagus

National Cancer Institute (NCI)

Phase 1 Unknown
25 enrolled
GastrointestinalOther neoplasm

Barrett Esophagus, Esophageal Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡